Methylene blue does not reverse existing neurofibrillary tangle pathology in the rTg4510 mouse model of tauopathy

Neuroscience Letters

Volumn 562, Issue , 2014, Pages 63-68

  Spires Jones, Tara L ^a,c   Friedman, Taylor ^a   Pitstick, Rose ^b   Polydoro, Manuela ^a   Roe, Allyson ^a   Carlson, George A ^b   Hyman, Bradley T ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b MCLAUGHLIN RESEARCH INSTITUTE   (United States)

^c UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

Alzheimer; Methylene blue; Tau

Indexed keywords

METHYLENE BLUE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN ATROPHY; CONTROLLED STUDY; DRUG PENETRATION; HEMISPHERE; HIPPOCAMPAL CA1 REGION; HIPPOCAMPUS; MOUSE; NEOCORTEX; NEUROFIBRILLARY TANGLE; NONHUMAN; PRIORITY JOURNAL; TAUOPATHY; TREATMENT DURATION;

ALZHEIMER; METHYLENE BLUE; TAU;

AMYLOID BETA-PEPTIDES; ANIMALS; DISEASE MODELS, ANIMAL; FEMALE; MALE; METHYLENE BLUE; MICE; MICE, 129 STRAIN; MICE, TRANSGENIC; NEUROFIBRILLARY TANGLES; TAU PROTEINS; TAUOPATHIES;

EID: 84893473873     PISSN: 03043940     EISSN: 18727972     Source Type: Journal    
DOI: 10.1016/j.neulet.2014.01.013     Document Type: Article

References (18)

1. Atamna H., Nguyen A., Schultz C., Boyle K., Newberry J., Kato H., Ames B.N. Methylene blue delays cellular senescence and enhances key mitochondrial biochemical pathways. FASEB J. 2008, 22:703-712.
2. Congdon E.E., Wu J.W., Myeku N., Figueroa Y.H., Herman M., Marinec P.S., Gestwicki J.E., Dickey C.A., Yu W.H., Duff K.E. Methylthioninium chloride (methylene blue) induces autophagy and attenuates tauopathy in vitro and in vivo. Autophagy 2012, 8:609-622.
3. de Calignon A., Polydoro M., Suárez-Calvet M., William C., Adamowicz D., Kopeikina K., Pitstick R., Sahara N., Ashe K., Carlson G., Spires-Jones T., Hyman B. Propagation of tau pathology in a model of early Alzheimer's disease. Neuron 2012, 73:685-697.
4. Gallyas F. Silver staining of Alzheimer's neurofibrillary changes by means of physical development. Acta Morphol. Acad. Sci. Hung. 1971, 19:1-8.
5. Hasegawa M., Arai T., Akiyama H., Nonaka T., Mori H., Hashimoto T., Yamazaki M., Oyanagi K. TDP-43 is deposited in the Guam parkinsonism-dementia complex brains. Brain 2007, 130:1386-1394.
6. Ingelsson M., Fukumoto H., Newell K.L., Growdon J.H., Hedley-Whyte E.T., Frosch M.P., Albert M.S., Hyman B.T., Irizarry M.C. Early Abeta accumulation and progressive synaptic loss, gliosis, and tangle formation in AD brain. Neurology 2004, 62:925-931.
7. Kopeikina K.J., Hyman B.T., Spires-Jones T.L. Soluble forms of tau are toxic in Alzheimer's disease. Transl. Neurosci. 2012, 3:223-233.
8. Medina D.X., Caccamo A., Oddo S. Methylene blue reduces abeta levels and rescues early cognitive deficit by increasing proteasome activity. Brain Pathol. 2011, 21:140-149.
9. Karran E., Mercken M., De Strooper B. The amyloid cascade hypothesis for Alzheimer's disease: an appraisal for the development of therapeutics. Nat. Rev. Drug Discov. 2011, 10:698-712.
10. Mosnaim A.D., Ranade V.V., Wolf M.E., Puente J., Antonieta Valenzuela M. Phenothiazine molecule provides the basic chemical structure for various classes of pharmacotherapeutic agents. Am. J. Ther. 2006, 13:261-273.
11. O'Leary J.C., Li Q., Marinec P., Blair L.J., Congdon E.E., Johnson A.G., Jinwal U.K., Koren J., 3rd J.R., Jones C., Kraft M., Peters J.F., Abisambra K.E., Duff E.J., Weeber J.E., Gestwicki C.A., Dickey Phenothiazine-mediated rescue of cognition in tau transgenic mice requires neuroprotection and reduced soluble tau burden. Mol. Neurodegener. 2010, 5:45.
12. Polydoro M., de Calignon A., Suarez-Calvet M., Sanchez L., Kay K.R., Nicholls S.B., Roe A.D., Pitstick R., Carlson G.A., Gomez-Isla T., Spires-Jones T.L., Hyman B.T. Reversal of neurofibrillary tangles and tau-associated phenotype in the rTgTauEC model of early Alzheimer's disease. J. Neurosci. 2013, 33:13300-13311.
13. Rojas J.C., Bruchey A.K., Gonzalez-Lima F. Neurometabolic mechanisms for memory enhancement and neuroprotection of methylene blue. Prog. Neurobiol. 2012, 96:32-45.
14. SantaCruz K., Lewis J., Spires T., Paulson J., Kotilinek L., Ingelsson M., Guimaraes A., DeTure M., Ramsden M., McGowan E., Forster C., Yue M., Orne J., Janus C., Mariash A., Kuskowski M., Hyman B., Hutton M., Ashe K.H. Tau suppression in a neurodegenerative mouse model improves memory function. Science 2005, 309:476-481.
15. Schirmer R.H., Adler H., Pickhardt M., Mandelkow E. Lest we forget you-methylene blue. Neurobiol. Aging 2011, 32:2325e7-2325e16.
16. Spires T.L., Orne J.D., SantaCruz K., Pitstick R., Carlson G.A., Ashe K.H., Hyman B.T. Region-specific dissociation of neuronal loss and neurofibrillary pathology in a mouse model of tauopathy. Am. J. Pathol. 2006, 168:1598-1607.
17. Taniguchi S., Suzuki N., Masuda M., Hisanaga S., Iwatsubo T., Goedert M., Hasegawa M. Inhibition of heparin-induced tau filament formation by phenothiazines, polyphenols, and porphyrins. J. Biol. Chem. 2005, 280:7614-7623.
18. Wischik C.M., Edwards P.C., Lai R.Y., Roth M., Harrington C.R. Selective inhibition of Alzheimer disease-like tau aggregation by phenothiazines. Proc. Natl. Acad. Sci. U.S.A. 1996, 93:11213-11218.